Our in vivo data showed that Rapa, used as a positive control, modulated mTOR phosphorylation to ameliorate clinical symptoms of AD by reducing epidermal and dermal thickness, inflammatory cell infiltration, and serum IgE and Th1/2 cytokine levels in the skin of AD-like skin lesion mice, which is consistent with previous studies (36). This evidence concerns the gene TRERF1 and Alzheimer disease.